Navigation Links
HPV vaccine works for boys: Study shows first clear benefits
Date:2/4/2011

The vaccine for human papillomavirus (HPV) can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

The four-year, international clinical trial, which also found a nearly 66 percent effectiveness in the general population of young men regardless of prior exposure to these strains, provides the first reported results of using the HPV vaccine as a prophylactic in men.

Initial data from this study informed the Food and Drug Administration's decision to approve the vaccine for boys in 2009 to prevent warts, while results from a substudy led the FDA to expand approval late last year to prevent anal cancer. Findings can be found in the Feb. 3 issue of the New England Journal of Medicine, or online at www.nejm.org.

While the HPV vaccine was approved in 2006 for girls to prevent cervical cancer, the vaccine's benefit for young men was not initially addressed. Yet infection and diseases caused by HPV are common in men, the researchers said, including genital warts, which are one of the leading sexually transmitted diseases (STD) for which treatment is sought nationwide. The Centers for Disease Control and Prevention estimate that half of all sexually active Americans will get HPV at some point in their lives.

"This is an exciting development in the STD world," said Joel Palefsky, MD, a UCSF professor of medicine who co-led the research along with epidemiologist Anna R. Giuliano, PhD, from the H. Lee Moffitt Cancer Center and Research Institute, in Tampa, FL. "It shows that if we vaccinate males early enough, we should be able to prevent most cases of external genital warts in this population."

While warts are often considered an annoyance, rather than a life-threatening disease such as cervical cancer, Palefsky noted that warts are a common problem in young people and are often associated with depression, social stigma and loss of self-esteem. Complications of wart treatments are also quite common, he said.

The double-blind study included 4,065 healthy men aged 16-26 years, spanning 71 sites in 18 countries. Of those patients, 85 percent reported having exclusively female sexual partners, with the remainder self-identified as having sex with men.

The men were tested at the onset of the trial for previous exposure to each strain and were randomly selected to receive either a placebo or a vaccine that targeted HPV strains 6, 11, 16 and 18. Men with a history of anal or genital warts or lesions were excluded. Participants then received six follow-up examinations over the following three years to assess the vaccine's effectiveness.

In addition to preventing warts, the vaccine also effectively prevented HPV-persistent infection in 86 percent of the participants without previous exposure.

"This is the first study to show that this vaccine works in boys," Giuliano said. "As long as we have a poor record of vaccinations in girls, boys should also be vaccinated."

Vaccinating boys also should help prevent HPV transmission to women, as well as transmission from men to men, she said, and help reduce the incidence of the virus throughout the general population. This could be particularly significant, Palefsky added, since only 30 to 40 percent of teenage girls in the U.S. have received even one of the three recommended doses of the vaccine.

The authors noted that while they find it likely that the prevention of HPV infection and disease in men will have additional benefits, such as preventing anal, genital and throat cancers, these benefits need to be directly demonstrated through further clinical trials.


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. New strategy produces promising advance in cancer vaccines
4. Screens, Vaccine for HPV Less Beneficial in Older Women
5. New Technology Could Widen Reach of Vaccines
6. Texas-based consortium announces groundbreaking vaccine research program
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. Possible vaccine for mesothelioma proven safe
9. Groundbreaking research to find vaccine for hepatitis C
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: